{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:51:50Z","timestamp":1792266710157,"version":"4.4.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Pediatric Hodgkin lymphoma (HL) has been treated successfully with risk-adapted and response-adapted therapy. While risk factors like Ann Arbor staging system, B symptoms, bulky disease, and erythrocyte sedimentation rate were measured objectively, B symptoms are subjective tools. We evaluated whether the neutrophil-to-lymphocyte ratio (NLR) and inflammatory marker levels correlated with B symptoms and disease burden.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and Methods:<\/jats:title>\n            <jats:p>We conducted a retrospective chart review of all children \u226414 years old with pathology-confirmed HL treated at our institution. Data included clinical and pathologic features, pretreatment erythrocyte sedimentation rate, ferritin levels; monocyte, neutrophil, and lymphocyte counts; and NLR. Optimum cutoffs of variables significantly associated with B symptoms were determined based on receiver operating characteristic curves.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Sixty-four patients were included in the analysis. Sixteen patients (25%) had B symptoms. Patients with B symptoms had higher ferritin levels (<jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.0001), monocyte counts (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.0060), neutrophil counts (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.0003) and NLR (<jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.0001), and lower lymphocyte counts (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.0017). Multiple receiver operating characteristic curves were generated to identify the optimum cutoff. Sensitivities and specificities of NLR (cutoff, 3.5) and ferritin (cutoff, 173\u2009ng\/mL) were the highest (81.25% and 81.25% [<jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.0001] and 89.36% and 75% [<jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.0001], respectively). Patients with NLR &gt;3.5 and ferritin &gt;173 (ng\/mL) had significantly higher stage, bulky disease, and B symptoms. NLR and ferritin are not predictive of worst outcome in the cohort analyzed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>NLR and ferritin levels were associated with high disease burden and B symptoms. Therefore, these variables can be used as measurable tools for B symptoms that can help stratify patients with HL. Larger and prospective studies are needed to validate these findings.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mph.0000000000002346","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T13:52:34Z","timestamp":1634737954000},"page":"e567-e571","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Neutrophil-to-Lymphocyte Ratio and Ferritin as Measurable Tools for Disease Burden and B Symptoms in Pediatric Patients With Hodgkin Lymphoma"],"prefix":"10.1097","volume":"44","author":[{"given":"Saja","family":"Jan","sequence":"first","affiliation":[{"name":"Princess Nora Oncology Center, King Abdulaziz Medical City, Ministry of National Guard Health Affairs"},{"name":"King Abdullah International Medical Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omima","family":"Mustafa","sequence":"additional","affiliation":[{"name":"Princess Nora Oncology Center, King Abdulaziz Medical City, Ministry of National Guard Health Affairs"},{"name":"King Abdullah International Medical Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Elgaml","sequence":"additional","affiliation":[{"name":"Princess Nora Oncology Center, King Abdulaziz Medical City, Ministry of National Guard Health Affairs"},{"name":"King Abdullah International Medical Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehal","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Princess Nora Oncology Center, King Abdulaziz Medical City, Ministry of National Guard Health Affairs"},{"name":"King Abdullah International Medical Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adil","family":"Abbas","sequence":"additional","affiliation":[{"name":"Princess Nora Oncology Center, King Abdulaziz Medical City, Ministry of National Guard Health Affairs"},{"name":"King Abdullah International Medical Research Center"},{"name":"King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Althubaiti","sequence":"additional","affiliation":[{"name":"Princess Nora Oncology Center, King Abdulaziz Medical City, Ministry of National Guard Health Affairs"},{"name":"King Abdullah International Medical Research Center"},{"name":"King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,10,14]]},"reference":[{"key":"R1-20250805","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1200\/JCO.2000.18.7.1500","article-title":"Localized childhood Hodgkin\u2019s disease: response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy\u2014results of the French Society of Pediatric Oncology study MDH90","volume":"18","author":"Landman-Parker","year":"2000","journal-title":"J Clin Oncol"},{"key":"R2-20250805","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1002\/cncr.28748","article-title":"Declining childhood and adolescent cancer mortality","volume":"120","author":"Smith","year":"2014","journal-title":"Cancer"},{"key":"R3-20250805","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1200\/JCO.2002.12.007","article-title":"Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin\u2019s disease who achieve a complete response to chemotherapy","volume":"20","author":"Nachman","year":"2002","journal-title":"J Clin Oncol"},{"key":"R4-20250805","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1200\/JCO.1997.15.8.2769","article-title":"Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin\u2019s disease in pediatric patients: a Pediatric Oncology Group study","volume":"15","author":"Weiner","year":"1997","journal-title":"J Clin Oncol"},{"key":"R5-20250805","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1200\/JCO.2013.52.5410","article-title":"Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk Hodgkin lymphoma: a report from the Children\u2019s Oncology Group study AHOD0031","volume":"32","author":"Friedman","year":"2014","journal-title":"J Clin Oncol"},{"key":"R6-20250805","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1002\/cncr.31519","article-title":"Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: a report from the Children\u2019s Oncology Group","volume":"124","author":"Keller","year":"2018","journal-title":"Cancer"},{"key":"R7-20250805","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.ijrobp.2016.07.015","article-title":"Predictive factor analysis of response-adapted radiation therapy for chemotherapy-sensitive pediatric Hodgkin lymphoma: analysis of the Children\u2019s Oncology Group AHOD 0031 trial","volume":"96","author":"Charpentier","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R8-20250805","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1097\/MPH.0000000000001076","article-title":"Excellent outcomes following response-based omission of radiotherapy in children and adolescents with intermediate or high-risk Hodgkin lymphoma","volume":"40","author":"Ozuah","year":"2018","journal-title":"J Pediatr Hematol Oncol"},{"key":"R9-20250805","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1200\/JCO.2009.26.9381","article-title":"Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin\u2019s lymphoma: the GPOH-HD-2002 study","volume":"28","author":"Mauz-K\u00f6rholz","year":"2010","journal-title":"J Clin Oncol"},{"key":"R10-20250805","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1182\/blood-2008-10-184143","article-title":"A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425","volume":"114","author":"Schwartz","year":"2009","journal-title":"Blood"},{"key":"R11-20250805","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/pbc.24279","article-title":"Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children\u2019s Oncology Group","volume":"59","author":"Tebbi","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"R12-20250805","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejca.2015.09.003","article-title":"The prognostic value of biological markers in paediatric Hodgkin lymphoma","volume":"52","author":"Farruggia","year":"2016","journal-title":"Eur J Cancer"},{"key":"R13-20250805","doi-asserted-by":"crossref","first-page":"e26278","DOI":"10.1002\/pbc.26278","article-title":"Childhood Hodgkin International Prognostic Score (CHIPS) predicts event-free survival in Hodgkin lymphoma: a report from the Children\u2019s Oncology Group","volume":"64","author":"Schwartz","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"R14-20250805","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/oxfordjournals.annonc.a059218","article-title":"Serum cytokine levels correlate with clinical parameters in Hodgkin\u2019s disease","volume":"6","author":"Gorschl\u00fcter","year":"1995","journal-title":"Ann Oncol"},{"key":"R15-20250805","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1182\/blood-2002-01-0099","article-title":"The role of cytokines in classical Hodgkin lymphoma","volume":"99","author":"Skinnider","year":"2002","journal-title":"Blood"},{"key":"R16-20250805","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1200\/JCO.2010.32.8401","article-title":"Molecular pathogenesis of Hodgkin\u2019s lymphoma: increasing evidence of the importance of the microenvironment","volume":"29","author":"Steidl","year":"2011","journal-title":"J Clin Oncol"},{"key":"R17-20250805","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/path.2711","article-title":"The classical Hodgkin\u2019s lymphoma microenvironment and its role in promoting tumour growth and immune escape","volume":"221","author":"Aldinucci","year":"2010","journal-title":"J Pathol"},{"key":"R18-20250805","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.3109\/10428194.2015.1038709","article-title":"Serum ferritin as prognostic marker in classical Hodgkin lymphoma treated with ABVD-based therapy","volume":"56","author":"Fernandez-Alvarez","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"R19-20250805","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/hon.2359","article-title":"Neutrophil\u2013lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: results of a large multicenter study involving 990 patients","volume":"35","author":"Marcheselli","year":"2017","journal-title":"Hematol Oncol"},{"key":"R20-20250805","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/bjh.15054","article-title":"Pre-treatment neutrophil\/lymphocyte ratio and platelet\/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma","volume":"180","author":"Reddy","year":"2018","journal-title":"Br J Haematol"},{"key":"R21-20250805","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1309\/AJCPO46GFKGNXCBR","article-title":"Prognostic significance of the ratio of absolute neutrophil count to absolute lymphocyte count in classic Hodgkin lymphoma","volume":"138","author":"Koh","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"R22-20250805","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s00277-018-3276-y","article-title":"Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy","volume":"97","author":"Romano","year":"2018","journal-title":"Ann Hematol"},{"key":"R23-20250805","doi-asserted-by":"crossref","first-page":"8735","DOI":"10.1002\/cam4.3396","article-title":"The neutrophil to lymphocyte ratio (NLR) and the presence of large nodal mass are independent predictors of early response: a subanalysis of the prospective phase II PET-2-adapted HD0607 trial","volume":"9","author":"Romano","year":"2020","journal-title":"Cancer Med"},{"key":"R24-20250805","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41568-020-0281-y","article-title":"Neutrophil diversity and plasticity in tumour progression and therapy","volume":"20","author":"Jaillon","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"R25-20250805","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/hon.878","article-title":"Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma","volume":"27","author":"Schreck","year":"2009","journal-title":"Hematol Oncol"},{"key":"R26-20250805","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/bjh.13198","article-title":"Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin lymphoma patients treated up-front with a risk-adapted strategy","volume":"168","author":"Romano","year":"2015","journal-title":"Br J Haematol"},{"key":"R27-20250805","doi-asserted-by":"crossref","first-page":"67333","DOI":"10.18632\/oncotarget.12024","article-title":"The prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin lymphoma","volume":"7","author":"Romano","year":"2016","journal-title":"Oncotarget"},{"key":"R28-20250805","doi-asserted-by":"crossref","first-page":"e1356965","DOI":"10.1080\/2162402X.2017.1356965","article-title":"Tumor-associated neutrophils induce apoptosis of non-activated CD8 T-cells in a TNF\u03b1 and NO-dependent mechanism, promoting a tumor-supportive environment","volume":"6","author":"Michaeli","year":"2017","journal-title":"OncoImmunology"},{"key":"R29-20250805","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1182\/blood-2006-04-015958","article-title":"Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL","volume":"109","author":"Chiu","year":"2007","journal-title":"Blood"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002346","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T01:01:06Z","timestamp":1754355666000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,14]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000002346","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10,14]]},"assertion":[{"value":"2020-12-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}